SWI/SNF染色质重塑复合物BAF亚基缺失性肺癌1例  

SWI/SNF chromatin remodeling complex BAF subunit-deficient lung carcinoma:a case report

作　　者：车冠华 倪磊[2] 陈晓炎[1] Che Guanhua;Ni Lei;Chen Xiaoyan(Department of Pathology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Respiratory and Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院病理科,上海200025 [2]上海交通大学医学院附属瑞金医院呼吸与危重症医学科,上海200025

出　　处：《中华结核和呼吸杂志》2024年第11期1102-1105,共4页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：海南省卫生健康行业科研项目(22A200173)。

摘　　要：SWI/SNF染色质重塑复合物BAF亚基(SMARCB1)缺失性肺癌罕见,可能适合免疫治疗。本文报道1例老年男性患者,因无明显诱因干咳3个月就诊,经支气管镜活检病理检查提示非小细胞肺癌,免疫组织化学染色SMARCB1(-)、SMARCA4(+)、PD-L1(22C3)肿瘤细胞阳性比例评分(TPS)为60%、Ki-67(+)阳性指数为60%,诊断为SMARCB1缺失性肺癌,给予化疗联合免疫治疗,随访34个月,患者目前带瘤生存。SWI/SNF chromatin remodeling complex BAF subunit(SMARCB1)-deficient lung carcinoma is rare and may be suitable for immunotherapy.This article presents the case of an elderly male who presented with"a persistent dry cough for 3 months without obvious inducement",and was initially diagnosed with non-small cell lung carcinoma following bronchoscopic biopsy.Immunohistochemical staining for SMARCB1(-),SMARCA4(+),PD-L1(22C3)(tumor proportion score is 60%),Ki-67(+)with a positive index of 60%.The final diagnosis is SMARCB1-deficient lung carcinoma.He was subsequently treated once with a combination of chemotherapy and immunotherapy,and has been followed up for 34 months.Currently,the patient continues to survive with tumor.

关 键 词：阳性指数 带瘤生存 非小细胞肺癌 免疫治疗 阳性比例 免疫组织化学染色 缺失性 病理检查 

分 类 号：R734.2[医药卫生—肿瘤]